Drug Trial Radar · NCT00279045
Diabetes Study With Rosiglitazone Monotherapy Versus Metformin Or Glyburide/Glibenclamide
Last checked: Nov 20, 2026Latest source record: Nov 29, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
4,426
Actual
Start
Jan 3, 2000
Primary completion
Jun 1, 2006
Study completion Jun 19, 2006
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Jan 19, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Primary purpose
- Treatment
- Who can join
- All sexes, from 30 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will compare and evaluate the effects of long-term treatment of monotherapy with rosiglitazone, metformin and glyburide/glibenclamide on the improvement and maintenance of glycemic control in patients with recently diagnosed type 2 diabetes mellitus.
Conditions
- Diabetes Mellitus, Type 2
Interventions
RosiglitazoneDrug
glyburideDrug
metforminDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time from randomization to the primary action point (monotherapy failure).
Locations
490 sites in 17 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Anniston, Alabama
GSK Investigational Site
Birmingham, Alabama
GSK Investigational Site
Mesa, Arizona
GSK Investigational Site
Tucson, Arizona
GSK Investigational Site
Little Rock, Arkansas
GSK Investigational Site
Berkeley, California
GSK Investigational Site
Corona, California
GSK Investigational Site
Fair Oaks, California
GSK Investigational Site
Fremont, California
GSK Investigational Site
Fresno, California
GSK Investigational Site
Fullerton, California
GSK Investigational Site
Greenbrae, California
GSK Investigational Site
Harbor City, California
GSK Investigational Site
Healdsburg, California
GSK Investigational Site
La Jolla, California
GSK Investigational Site
Loma Linda, California
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
Modesto, California
GSK Investigational Site
Pasadena, California
GSK Investigational Site
San Diego, California
GSK Investigational Site
San Francisco, California
GSK Investigational Site
Santa Rosa, California
GSK Investigational Site
Sunnyvale, California
GSK Investigational Site
Ukiah, California
GSK Investigational Site
Walnut Creek, California
GSK Investigational Site
Yorba Linda, California
GSK Investigational Site
Boulder, Colorado
GSK Investigational Site
Denver, Colorado
GSK Investigational Site
Denver, Colorado
GSK Investigational Site
Englewood, Colorado
GSK Investigational Site
Longmont, Colorado
GSK Investigational Site
Wheat Ridge, Colorado
GSK Investigational Site
Wheat Ridge, Colorado
GSK Investigational Site
Washington D.C., District of Columbia
GSK Investigational Site
Washington D.C., District of Columbia
GSK Investigational Site
Fort Myers, Florida
GSK Investigational Site
Hollywood, Florida
GSK Investigational Site
Jacksonville, Florida
GSK Investigational Site
Jacksonville, Florida
Showing 40 of 490 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.